Sun Pharmaceuticals Industries Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: July 5, 2025, 12:15 pm

Market Cap	4,02,201 Cr.
Current Price	1,676
High / Low	1,960/1,550
Stock P/E	35.1
Book Value	301
Dividend Yield	0.95 %
ROCE	20.2 %
ROE	16.9 %
Face Value	1.00
PEG Ratio	1.16

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Sun Pharmaceuticals Industries Ltd

Competitors of Sun Pharmaceuticals Industries Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	141 Cr.	100	247/84.3	27.3	41.7	0.00 %	12.9 %	9.75 %	10.0
MPS Pharmaa Ltd	5.48 Cr.	2.87	4.33/2.50		0.57	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	38.7 Cr.	52.2	94.9/45.2		8.73	0.00 %	41.5 %	14.4 %	10.0
Gujarat Inject (Kerala) Ltd	36.3 Cr.	24.8	29.1/13.1	35.6	6.83	0.00 %	13.5 %	11.0 %	10.0
Industry Average	19,115.98 Cr	1,198.62		105.17	194.43	0.30%	16.64%	15.18%	6.18

All Competitor Stocks of Sun Pharmaceuticals Industries Ltd

Quarterly Result

Metric	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	9,447	10,762	10,952	11,241	10,931	11,941	12,192	12,381	11,983	12,653	13,291	13,675	12,959
Expenses	7,106	7,877	7,996	8,237	8,129	8,609	9,013	8,904	8,948	9,045	9,352	9,666	9,243
Operating Profit	2,340	2,884	2,957	3,004	2,802	3,332	3,179	3,477	3,035	3,608	3,939	4,009	3,716
OPM %	25%	27%	27%	27%	26%	28%	26%	28%	25%	29%	30%	29%	29%
Other Income	-3,822	2	85	174	202	-118	294	180	504	533	354	149	251
Interest	37	14	19	46	93	81	49	35	74	62	69	52	49
Depreciation	556	588	610	660	672	651	633	622	650	655	626	631	664
Profit before tax	-2,076	2,285	2,412	2,471	2,240	2,481	2,791	3,000	2,816	3,424	3,598	3,476	3,254
Tax %	7%	8%	6%	11%	10%	19%	14%	14%	5%	16%	16%	16%	34%
Net Profit	-2,227	2,093	2,256	2,181	1,983	2,006	2,385	2,561	2,659	2,861	3,037	2,913	2,154
EPS in Rs	-9.49	8.59	9.43	9.03	8.27	8.43	9.90	10.52	11.06	11.82	12.67	12.10	8.96

Last Updated: May 31, 2025, 7:39 am

Below is a detailed analysis of the quarterly data for Sun Pharmaceuticals Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 12,959.00 Cr.. The value appears to be declining and may need further review. It has decreased from 13,675.00 Cr. (Dec 2024) to 12,959.00 Cr., marking a decrease of 716.00 Cr..
For Expenses, as of Mar 2025, the value is 9,243.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 9,666.00 Cr. (Dec 2024) to 9,243.00 Cr., marking a decrease of 423.00 Cr..
For Operating Profit, as of Mar 2025, the value is 3,716.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,009.00 Cr. (Dec 2024) to 3,716.00 Cr., marking a decrease of 293.00 Cr..
For OPM %, as of Mar 2025, the value is 29.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 29.00%.
For Other Income, as of Mar 2025, the value is 251.00 Cr.. The value appears strong and on an upward trend. It has increased from 149.00 Cr. (Dec 2024) to 251.00 Cr., marking an increase of 102.00 Cr..
For Interest, as of Mar 2025, the value is 49.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 52.00 Cr. (Dec 2024) to 49.00 Cr., marking a decrease of 3.00 Cr..
For Depreciation, as of Mar 2025, the value is 664.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 631.00 Cr. (Dec 2024) to 664.00 Cr., marking an increase of 33.00 Cr..
For Profit before tax, as of Mar 2025, the value is 3,254.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,476.00 Cr. (Dec 2024) to 3,254.00 Cr., marking a decrease of 222.00 Cr..
For Tax %, as of Mar 2025, the value is 34.00%. The value appears to be increasing, which may not be favorable. It has increased from 16.00% (Dec 2024) to 34.00%, marking an increase of 18.00%.
For Net Profit, as of Mar 2025, the value is 2,154.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,913.00 Cr. (Dec 2024) to 2,154.00 Cr., marking a decrease of 759.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 8.96. The value appears to be declining and may need further review. It has decreased from 12.10 (Dec 2024) to 8.96, marking a decrease of 3.14.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 3:55 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	16,080	27,392	28,487	31,578	26,489	29,066	32,838	33,498	38,654	43,886	48,497	52,578
Expenses	9,078	19,498	20,313	21,476	20,858	22,689	25,855	25,028	28,397	32,235	35,479	37,307
Operating Profit	7,003	7,894	8,174	10,102	5,631	6,377	6,983	8,470	10,258	11,650	13,018	15,272
OPM %	44%	29%	29%	32%	21%	22%	21%	25%	27%	27%	27%	29%
Other Income	-1,968	283	-42	610	-135	-258	382	-3,449	-3,505	459	865	1,287
Interest	44	579	523	400	518	555	303	141	127	172	238	231
Depreciation	409	1,195	1,038	1,265	1,500	1,753	2,053	2,080	2,144	2,529	2,557	2,575
Profit before tax	4,581	6,403	6,571	9,048	3,479	3,810	5,010	2,799	4,481	9,408	11,088	13,752
Tax %	15%	14%	14%	13%	26%	16%	16%	18%	24%	9%	13%	20%
Net Profit	3,879	5,476	5,658	7,846	2,542	3,208	4,172	2,272	3,389	8,513	9,610	10,965
EPS in Rs	15.17	21.92	18.89	29.03	8.73	11.11	15.69	12.10	13.64	35.32	39.91	45.55
Dividend Payout %	10%	14%	5%	12%	23%	25%	25%	62%	73%	33%	34%	35%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	41.17%	3.32%	38.67%	-67.60%	26.20%	30.05%	-45.54%	49.16%	151.20%	12.89%	14.10%
Change in YoY Net Profit Growth (%)	0.00%	-37.85%	35.35%	-106.27%	93.80%	3.85%	-75.59%	94.71%	102.03%	-138.31%	1.21%

Sun Pharmaceuticals Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	7%
5 Years:	10%
3 Years:	11%
TTM:	8%

Compounded Profit Growth
10 Years:	10%
5 Years:	24%
3 Years:	20%
TTM:	15%

Stock Price CAGR
10 Years:	7%
5 Years:	28%
3 Years:	26%
1 Year:	7%

Return on Equity
10 Years:	14%
5 Years:	15%
3 Years:	17%
Last Year:	17%

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 11:17 am

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	207	207	241	240	240	240	240	240	240	240	240	240
Reserves	18,318	25,431	32,742	36,400	38,074	41,169	45,025	46,223	47,771	55,755	63,427	71,978
Borrowings	2,561	8,996	8,497	9,832	10,385	10,514	8,315	3,869	1,290	6,886	3,274	2,362
Other Liabilities	8,009	14,089	13,948	14,624	15,598	12,666	14,615	17,291	20,474	17,831	18,367	17,520
Total Liabilities	29,095	48,723	55,428	61,095	64,297	64,590	68,194	67,622	69,776	80,712	85,308	92,101
Fixed Assets	6,817	12,682	15,872	17,675	18,853	21,837	22,847	21,553	22,665	24,065	23,211	27,996
CWIP	842	2,039	2,175	2,801	2,465	1,411	1,220	1,567	1,287	4,973	5,354	1,234
Investments	2,786	2,716	1,830	1,192	7,143	7,903	10,143	9,612	12,849	14,824	15,026	18,354
Other Assets	18,650	31,286	35,550	39,427	35,837	33,439	33,984	34,890	32,975	36,849	41,717	44,517
Total Assets	29,095	48,723	55,428	61,095	64,297	64,590	68,194	67,622	69,776	80,712	85,308	92,101

Below is a detailed analysis of the balance sheet data for Sun Pharmaceuticals Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Equity Capital, as of Mar 2025, the value is 240.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 240.00 Cr..
For Reserves, as of Mar 2025, the value is 71,978.00 Cr.. The value appears strong and on an upward trend. It has increased from 63,427.00 Cr. (Mar 2024) to 71,978.00 Cr., marking an increase of 8,551.00 Cr..
For Borrowings, as of Mar 2025, the value is 2,362.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 3,274.00 Cr. (Mar 2024) to 2,362.00 Cr., marking a decrease of 912.00 Cr..
For Other Liabilities, as of Mar 2025, the value is 17,520.00 Cr.. The value appears to be improving (decreasing). It has decreased from 18,367.00 Cr. (Mar 2024) to 17,520.00 Cr., marking a decrease of 847.00 Cr..
For Total Liabilities, as of Mar 2025, the value is 92,101.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 85,308.00 Cr. (Mar 2024) to 92,101.00 Cr., marking an increase of 6,793.00 Cr..
For Fixed Assets, as of Mar 2025, the value is 27,996.00 Cr.. The value appears strong and on an upward trend. It has increased from 23,211.00 Cr. (Mar 2024) to 27,996.00 Cr., marking an increase of 4,785.00 Cr..
For CWIP, as of Mar 2025, the value is 1,234.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,354.00 Cr. (Mar 2024) to 1,234.00 Cr., marking a decrease of 4,120.00 Cr..
For Investments, as of Mar 2025, the value is 18,354.00 Cr.. The value appears strong and on an upward trend. It has increased from 15,026.00 Cr. (Mar 2024) to 18,354.00 Cr., marking an increase of 3,328.00 Cr..
For Other Assets, as of Mar 2025, the value is 44,517.00 Cr.. The value appears strong and on an upward trend. It has increased from 41,717.00 Cr. (Mar 2024) to 44,517.00 Cr., marking an increase of 2,800.00 Cr..
For Total Assets, as of Mar 2025, the value is 92,101.00 Cr.. The value appears strong and on an upward trend. It has increased from 85,308.00 Cr. (Mar 2024) to 92,101.00 Cr., marking an increase of 6,793.00 Cr..

Notably, the Reserves (71,978.00 Cr.) exceed the Borrowings (2,362.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Month		Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Cash from Operating Activity +	3,959	5,616	6,686	7,082	3,907	2,196	6,555	6,170	8,985	4,959	12,135	14,072
Cash from Investing Activity +	-2,176	-1,502	-3,949	-4,186	-3,104	-310	-2,225	407	-5,556	-7,220	-763	-5,306
Cash from Financing Activity +	507	-1,187	-1,889	-2,285	-1,539	-2,731	-5,715	-5,980	-5,193	2,376	-6,710	-7,906
Net Cash Flow	2,290	2,927	848	611	-736	-844	-1,386	596	-1,765	115	4,662	860

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	5.00	-1.00	0.00	1.00	-5.00	-4.00	-2.00	5.00	9.00	5.00	10.00	13.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	79	50	68	87	83	108	112	105	99	99	95	85
Inventory Days	454	410	307	370	307	338	366	311	378	315	360	338
Days Payable	186	174	178	207	197	234	192	142	167	158	194	194
Cash Conversion Cycle	347	286	197	251	193	212	285	274	310	255	261	229
Working Capital Days	111	126	76	104	73	79	137	112	84	55	93	78
ROCE %	32%	34%	23%	18%	20%	10%	10%	10%	13%	17%	16%	17%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%	54.48%
FIIs	14.44%	14.95%	16.00%	16.87%	16.88%	16.48%	16.78%	17.08%	17.72%	17.23%	18.01%	18.04%
DIIs	20.02%	19.66%	19.64%	19.08%	19.18%	19.65%	19.56%	19.42%	18.71%	19.17%	18.48%	18.43%
Government	0.00%	0.00%	0.06%	0.06%	0.06%	0.09%	0.10%	0.11%	0.11%	0.11%	0.11%	0.11%
Public	11.06%	10.91%	9.80%	9.52%	9.38%	9.28%	9.05%	8.92%	8.97%	9.00%	8.89%	8.92%
No. of Shareholders	6,62,384	6,47,167	6,43,512	6,32,337	6,25,252	6,24,561	6,16,588	6,12,626	6,31,392	6,73,217	6,57,317	6,89,623

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
SBI Nifty 50 ETF	19,868,445	1.43	2502.33	19,868,445	2025-04-22 17:25:19	0%
ICICI Prudential Value Discovery Fund	18,245,002	6.12	2297.87	18,245,002	2025-04-22 17:25:19	0%
SBI S&P BSE Sensex ETF	14,074,237	1.65	1773.35	14,074,237	2025-04-22 17:25:19	0%
ICICI Prudential Equity & Debt Fund	7,973,496	3.37	1004.22	7,973,496	2025-04-22 17:25:19	0%
ICICI Prudential Bluechip Fund	7,743,881	2.03	975.3	7,743,881	2025-04-22 17:25:19	0%
Axis Bluechip Fund	6,950,290	2.64	875.35	6,950,290	2025-04-22 11:41:35	0%
HDFC Balanced Advantage Fund - Regular Plan	6,700,612	1.15	843.91	6,700,612	2025-04-22 17:25:19	0%
Nippon India Pharma Fund	6,556,349	12.76	825.74	6,556,349	2025-04-22 17:25:19	0%
Aditya Birla Sun Life Flexi Cap Fund	6,516,359	4.24	820.7	6,516,359	2025-04-22 17:25:19	0%
HDFC Top 100 Fund - Regular Plan	6,434,009	2.68	810.33	6,434,009	2025-04-22 12:29:18	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	1.00	1.00	1.00	1.00	1.00
Basic EPS (Rs.)	45.60	39.90	35.30	13.60	12.10
Diluted EPS (Rs.)	45.60	39.90	35.30	13.60	12.10
Cash EPS (Rs.)	56.50	50.87	46.22	23.13	18.19
Book Value[Excl.RevalReserv]/Share (Rs.)	301.00	279.69	247.22	212.84	206.23
Book Value[Incl.RevalReserv]/Share (Rs.)	301.00	279.69	247.22	212.84	206.23
Revenue From Operations / Share (Rs.)	219.14	202.13	182.91	161.11	139.62
PBDIT / Share (Rs.)	71.84	59.92	51.19	47.18	38.87
PBIT / Share (Rs.)	61.11	49.27	40.64	38.24	30.20
PBT / Share (Rs.)	57.32	46.21	39.21	18.68	11.67
Net Profit / Share (Rs.)	45.76	40.21	35.68	14.20	9.52
NP After MI And SOA / Share (Rs.)	45.55	39.91	35.32	13.64	12.10
PBDIT Margin (%)	32.78	29.64	27.98	29.28	27.84
PBIT Margin (%)	27.88	24.37	22.22	23.73	21.63
PBT Margin (%)	26.15	22.86	21.43	11.59	8.35
Net Profit Margin (%)	20.88	19.89	19.50	8.81	6.82
NP After MI And SOA Margin (%)	20.78	19.74	19.30	8.46	8.66
Return on Networth / Equity (%)	15.13	15.04	15.13	6.81	6.24
Return on Capital Employeed (%)	19.83	17.26	16.02	17.44	14.06
Return On Assets (%)	11.86	11.20	10.49	4.68	4.29
Long Term Debt / Equity (X)	0.00	0.00	0.00	0.00	0.01
Total Debt / Equity (X)	0.02	0.04	0.11	0.01	0.07
Asset Turnover Ratio (%)	0.59	0.58	0.58	0.56	0.49
Current Ratio (X)	2.89	2.56	2.00	2.04	1.89
Quick Ratio (X)	2.33	1.98	1.48	1.51	1.33
Inventory Turnover Ratio (X)	0.64	0.67	0.79	0.78	0.72
Dividend Payout Ratio (NP) (%)	0.00	30.26	29.73	65.96	53.68
Dividend Payout Ratio (CP) (%)	0.00	23.88	22.89	39.85	31.28
Earning Retention Ratio (%)	0.00	69.74	70.27	34.04	46.32
Cash Earning Retention Ratio (%)	0.00	76.12	77.11	60.15	68.72
Interest Coverage Ratio (X)	74.50	60.29	71.40	88.88	65.95
Interest Coverage Ratio (Post Tax) (X)	51.39	43.53	51.77	63.60	47.60
Enterprise Value (Cr.)	407192.46	384570.80	239622.86	218440.19	143296.74
EV / Net Operating Revenue (X)	7.74	7.93	5.46	5.65	4.28
EV / EBITDA (X)	23.62	26.75	19.51	19.30	15.36
MarketCap / Net Operating Revenue (X)	7.92	8.02	5.37	5.68	4.28
Retention Ratios (%)	0.00	69.73	70.26	34.03	46.31
Price / BV (X)	5.77	6.11	4.21	4.57	3.09
Price / Net Operating Revenue (X)	7.92	8.02	5.37	5.68	4.28
EarningsYield	0.02	0.02	0.03	0.01	0.02

After reviewing the key financial ratios for Sun Pharmaceuticals Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
For Basic EPS (Rs.), as of Mar 25, the value is 45.60. This value is within the healthy range. It has increased from 39.90 (Mar 24) to 45.60, marking an increase of 5.70.
For Diluted EPS (Rs.), as of Mar 25, the value is 45.60. This value is within the healthy range. It has increased from 39.90 (Mar 24) to 45.60, marking an increase of 5.70.
For Cash EPS (Rs.), as of Mar 25, the value is 56.50. This value is within the healthy range. It has increased from 50.87 (Mar 24) to 56.50, marking an increase of 5.63.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 301.00. It has increased from 279.69 (Mar 24) to 301.00, marking an increase of 21.31.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 301.00. It has increased from 279.69 (Mar 24) to 301.00, marking an increase of 21.31.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 219.14. It has increased from 202.13 (Mar 24) to 219.14, marking an increase of 17.01.
For PBDIT / Share (Rs.), as of Mar 25, the value is 71.84. This value is within the healthy range. It has increased from 59.92 (Mar 24) to 71.84, marking an increase of 11.92.
For PBIT / Share (Rs.), as of Mar 25, the value is 61.11. This value is within the healthy range. It has increased from 49.27 (Mar 24) to 61.11, marking an increase of 11.84.
For PBT / Share (Rs.), as of Mar 25, the value is 57.32. This value is within the healthy range. It has increased from 46.21 (Mar 24) to 57.32, marking an increase of 11.11.
For Net Profit / Share (Rs.), as of Mar 25, the value is 45.76. This value is within the healthy range. It has increased from 40.21 (Mar 24) to 45.76, marking an increase of 5.55.
For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 45.55. This value is within the healthy range. It has increased from 39.91 (Mar 24) to 45.55, marking an increase of 5.64.
For PBDIT Margin (%), as of Mar 25, the value is 32.78. This value is within the healthy range. It has increased from 29.64 (Mar 24) to 32.78, marking an increase of 3.14.
For PBIT Margin (%), as of Mar 25, the value is 27.88. This value exceeds the healthy maximum of 20. It has increased from 24.37 (Mar 24) to 27.88, marking an increase of 3.51.
For PBT Margin (%), as of Mar 25, the value is 26.15. This value is within the healthy range. It has increased from 22.86 (Mar 24) to 26.15, marking an increase of 3.29.
For Net Profit Margin (%), as of Mar 25, the value is 20.88. This value exceeds the healthy maximum of 10. It has increased from 19.89 (Mar 24) to 20.88, marking an increase of 0.99.
For NP After MI And SOA Margin (%), as of Mar 25, the value is 20.78. This value exceeds the healthy maximum of 20. It has increased from 19.74 (Mar 24) to 20.78, marking an increase of 1.04.
For Return on Networth / Equity (%), as of Mar 25, the value is 15.13. This value is within the healthy range. It has increased from 15.04 (Mar 24) to 15.13, marking an increase of 0.09.
For Return on Capital Employeed (%), as of Mar 25, the value is 19.83. This value is within the healthy range. It has increased from 17.26 (Mar 24) to 19.83, marking an increase of 2.57.
For Return On Assets (%), as of Mar 25, the value is 11.86. This value is within the healthy range. It has increased from 11.20 (Mar 24) to 11.86, marking an increase of 0.66.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.04 (Mar 24) to 0.02, marking a decrease of 0.02.
For Asset Turnover Ratio (%), as of Mar 25, the value is 0.59. It has increased from 0.58 (Mar 24) to 0.59, marking an increase of 0.01.
For Current Ratio (X), as of Mar 25, the value is 2.89. This value is within the healthy range. It has increased from 2.56 (Mar 24) to 2.89, marking an increase of 0.33.
For Quick Ratio (X), as of Mar 25, the value is 2.33. This value exceeds the healthy maximum of 2. It has increased from 1.98 (Mar 24) to 2.33, marking an increase of 0.35.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 4. It has decreased from 0.67 (Mar 24) to 0.64, marking a decrease of 0.03.
For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 30.26 (Mar 24) to 0.00, marking a decrease of 30.26.
For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 23.88 (Mar 24) to 0.00, marking a decrease of 23.88.
For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 69.74 (Mar 24) to 0.00, marking a decrease of 69.74.
For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 76.12 (Mar 24) to 0.00, marking a decrease of 76.12.
For Interest Coverage Ratio (X), as of Mar 25, the value is 74.50. This value is within the healthy range. It has increased from 60.29 (Mar 24) to 74.50, marking an increase of 14.21.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 51.39. This value is within the healthy range. It has increased from 43.53 (Mar 24) to 51.39, marking an increase of 7.86.
For Enterprise Value (Cr.), as of Mar 25, the value is 407,192.46. It has increased from 384,570.80 (Mar 24) to 407,192.46, marking an increase of 22,621.66.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.74. This value exceeds the healthy maximum of 3. It has decreased from 7.93 (Mar 24) to 7.74, marking a decrease of 0.19.
For EV / EBITDA (X), as of Mar 25, the value is 23.62. This value exceeds the healthy maximum of 15. It has decreased from 26.75 (Mar 24) to 23.62, marking a decrease of 3.13.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.92. This value exceeds the healthy maximum of 3. It has decreased from 8.02 (Mar 24) to 7.92, marking a decrease of 0.10.
For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 69.73 (Mar 24) to 0.00, marking a decrease of 69.73.
For Price / BV (X), as of Mar 25, the value is 5.77. This value exceeds the healthy maximum of 3. It has decreased from 6.11 (Mar 24) to 5.77, marking a decrease of 0.34.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.92. This value exceeds the healthy maximum of 3. It has decreased from 8.02 (Mar 24) to 7.92, marking a decrease of 0.10.
For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Sun Pharmaceuticals Industries Ltd as of July 5, 2025 is: 1,441.97

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of July 5, 2025, Sun Pharmaceuticals Industries Ltd is Overvalued by 13.96% compared to the current share price 1,676.00

Intrinsic Value of Sun Pharmaceuticals Industries Ltd as of July 5, 2025 is: 1,879.74

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of July 5, 2025, Sun Pharmaceuticals Industries Ltd is Undervalued by 12.16% compared to the current share price 1,676.00

Last 5 Year EPS CAGR: 30.36%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 18.33%, which is a positive sign. The company has higher reserves (43,526.08 cr) compared to borrowings (6,398.42 cr), indicating strong financial stability. The company has shown consistent growth in sales (33.58 cr) and profit (6.25 cr) over the years.	The stock has a high average Working Capital Days of 94.00, which may not be favorable. The stock has a high average Cash Conversion Cycle of 258.33, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sun Pharmaceuticals Industries Ltd:
1. Net Profit Margin: 20.88%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 19.83% (Industry Average ROCE: 16.64%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 15.13% (Industry Average ROE: 15.18%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 51.39
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 2.33
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 35.1 (Industry average Stock P/E: 105.17)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.02
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Sun Pharmaceutical Industries Ltd. is a Public Limited Listed company incorporated on 01/03/1993 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24230GJ1993PLC019050 and registration number is 019050. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 23003.33 Cr. and Equity Capital is Rs. 239.93 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Sun Pharma Advanced Research Centre (SPARC), Tandalja, Vadodra Gujarat 390012	secretarial@sunpharma.com http://www.sunpharma.com

Management
Name	Position Held
Mr. Dilip S Shanghvi	Chairman & Managing Director
Mr. Aalok D Shanghvi	Executive Director
Ms. Vidhi Shanghvi	Executive Director
Mr. Sudhir V Valia	Non Exe.Non Ind.Director
Dr. Pawan Goenka	Lead Independent Director
Mr. Rama Bijapurkar	Independent Director
Mr. Gautam Doshi	Independent Director
Mr. Rolf Hoffmann	Independent Director

FAQ

What is the intrinsic value of Sun Pharmaceuticals Industries Ltd?

Sun Pharmaceuticals Industries Ltd's intrinsic value (as of 05 July 2025) is 1441.97 — 13.96% lower the current market price of 1,676.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 4,02,201 Cr. market cap, FY2025-2026 high/low of 1,960/1,550, reserves of 71,978 Cr, and liabilities of 92,101 Cr.

What is the Market Cap of Sun Pharmaceuticals Industries Ltd?

The Market Cap of Sun Pharmaceuticals Industries Ltd is 4,02,201 Cr..

What is the current Stock Price of Sun Pharmaceuticals Industries Ltd as on 05 July 2025?

The current stock price of Sun Pharmaceuticals Industries Ltd as on 05 July 2025 is 1,676.

What is the High / Low of Sun Pharmaceuticals Industries Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Sun Pharmaceuticals Industries Ltd stocks is ₹1,960/1,550.

What is the Stock P/E of Sun Pharmaceuticals Industries Ltd?

The Stock P/E of Sun Pharmaceuticals Industries Ltd is 35.1.

What is the Book Value of Sun Pharmaceuticals Industries Ltd?

The Book Value of Sun Pharmaceuticals Industries Ltd is 301.

What is the Dividend Yield of Sun Pharmaceuticals Industries Ltd?

The Dividend Yield of Sun Pharmaceuticals Industries Ltd is 0.95 %.

What is the ROCE of Sun Pharmaceuticals Industries Ltd?

The ROCE of Sun Pharmaceuticals Industries Ltd is 20.2 %.

What is the ROE of Sun Pharmaceuticals Industries Ltd?

The ROE of Sun Pharmaceuticals Industries Ltd is 16.9 %.

What is the Face Value of Sun Pharmaceuticals Industries Ltd?

The Face Value of Sun Pharmaceuticals Industries Ltd is 1.00.